Brookline Capital Markets Predicts Medicus Pharma Q1 Earnings

Medicus Pharma Ltd (NASDAQ:MDCX) – Investment analysts at Brookline Capital Markets issued their Q1 2026 earnings per share estimates for Medicus Pharma in a research report issued to clients and investors on Tuesday, March 31st. Brookline Capital Markets analyst K. Raja forecasts that the company will post earnings of ($0.20) per share for the quarter. The consensus estimate for Medicus Pharma’s current full-year earnings is ($1.14) per share. Brookline Capital Markets also issued estimates for Medicus Pharma’s Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.13) EPS and Q4 2026 earnings at ($0.10) EPS.

A number of other brokerages have also weighed in on MDCX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Medicus Pharma in a research report on Monday, December 29th. D. Boral Capital reissued a “buy” rating and issued a $27.00 price target on shares of Medicus Pharma in a research report on Thursday, March 19th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $23.50.

Medicus Pharma Stock Performance

Shares of Medicus Pharma stock opened at $0.46 on Wednesday. Medicus Pharma has a 52-week low of $0.37 and a 52-week high of $8.94. The stock’s 50-day simple moving average is $0.94 and its 200 day simple moving average is $1.68. The stock has a market capitalization of $11.73 million, a P/E ratio of -0.16 and a beta of -1.58.

Medicus Pharma (NASDAQ:MDCX) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.50).

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Armistice Capital LLC bought a new position in shares of Medicus Pharma in the fourth quarter worth $2,771,000. Private Advisor Group LLC boosted its stake in Medicus Pharma by 3.8% during the third quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock valued at $351,000 after buying an additional 5,500 shares during the period. Jane Street Group LLC bought a new stake in Medicus Pharma during the fourth quarter valued at $92,000. Wilmington Savings Fund Society FSB grew its position in Medicus Pharma by 100.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 51,244 shares of the company’s stock worth $78,000 after buying an additional 25,622 shares in the last quarter. Finally, Commonwealth Equity Services LLC grew its position in Medicus Pharma by 161.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock worth $44,000 after buying an additional 17,611 shares in the last quarter.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.